Dr. Ijen Chen
Dr. Ijen Chen is passionate about molecular recognition and has been working in structure based drug design for more than 20 years contributing to the discovery and optimization phases of various target classes such as GPCRs, Kinases, and Protein-Protein Interactions. She has co-authored peer-reviewed articles on both drug design and technology development. She is also an inventor on chemical patents from her collaborative work. Before joining Sosei Heptares, she was with Vernalis with a special focus on fragment based design. She obtained her BSc in Chemistry from Tsing Hua University in Taiwan and has a PhD in Computational Chemistry from Department of Pharmaceutical Sciences, University of Maryland in US.
Design and Synthesis of Pyrrolo[2,3-d]pyrimidine-Derived Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitors Using a Checkpoint Kinase 1 (CHK1)-Derived Crystallographic Surrogate
Williamson DS, Smith GP, Mikkelsen GK, Jensen T, Acheson-Dossang P, Badolo L, Bedford ST, Chell V, Chen I, Dokurno P, Hentzer M, Newland S, Ray SC, Shaw T, Surgenor AE, Terry L, Wang Y, Christensen KV
J Med Chem, 2021, 64(14):10312-10332
Discovery of S64315, a Potent and Selective Mcl-1 Inhibitor
Szlavik Z, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Murray J, Davidson J, Chen I, Dokurno P, Surgenor AE, Daniels ZM, Hubbard RE, Le Toumelin-Braizat G, Claperon A, Lysiak-Auvity G, Girard AM, Bruno A, Chanrion M, Colland F, Maragno AL, Demarles D, Geneste O, Kotschy A.
J Med Chem, 2020, 63(22):13762-13795
Modelling the binding mode of macrocycles: Docking and conformational sampling
Martin SJ, Chen I, Chan AWE, Foloppe N.
Bioorg Med Chem, 2020, 28(1):115143
Energy windows for computed compound conformers: covering artefacts or truly large reorganization energies?
Foloppe N and Chen I
Future Med Chem, 2019, 11(2):97-118
Towards understanding the unbound state of drug compounds: Implications for the intramolecular reorganization energy upon binding
Foloppe N and Chen I
Bioorg Med Chem, 2016, 24(10):2159-89
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
Kotschy A, Szlavik Z, Murray J, Davidson J, Maragno AL, Le Toumelin-Braizat G, Chanrion M, Kelly GL, Gong JN, Moujalled DM, Bruno A, Csekei M, Paczal A, Szabo ZB, Sipos S, Radics G, Proszenyak A, Balint B, Ondi L, Blasko G, Robertson A, Surgenor A, Dokurno P, Chen I, Matassova N, Smith J, Pedder C, Graham C, Studeny A, Lysiak-Auvity G, Girard AM, Gravé F, Segal D, Riffkin CD, Pomilio G, Galbraith LC, Aubrey BJ, Brennan MS, Herold MJ, Chang C, Guasconi G, Cauquil N, Melchiore F, Guigal-Stephan N, Lockhart B, Colland F, Hickman JA, Roberts AW, Huang DC, Wei AH, Strasser A, Lessene G, Geneste O.
Nature, 2016, 538: 477–482